Real-world data and real-world evidence are poised to keep making strides in 2023. This analysis of clinical evidence studies the usage, potential advantages and risk of a medical product inferred from the real-world data analysis. Real-world evidence (RWE) is accelerating its involvement in the early benefit elucidation of medicinal drugs.
RWE solutions have proven to be extremely useful, as they allow industrial and academic researchers to monitor patients using digitally connected platforms while assisting to organize and evaluate clinical data for regulatory submissions. Since RWE research is still in an evolution process, and few gaps in the area have been explored, more guidance and a consented annotation is obligatory to increase the effectuation of real-world data.
After five successful editions of Real-World Evidence and Life Sciences Analytics Conference in Boston, USA, MarketsandMarkets is proud to announce its upcoming Europe edition of Real-World Evidence and Life Sciences Analytics Conference to be held on October 5th- 6th 2023 in Frankfurt, Germany. The conference will bring the full spectrum of experts, leaders, and stakeholders to share a board prospective on significant points and hold discussions on the best practices with a key takeaway being better decision making.
Director Global Evidence & Value Development Oncology, Merck KGaA
Director Global Evidence & Value Development Oncology, Merck KGaA
Associate Director, Real World Data Europe/ International Value, Evidence, and Outcomes (VEO) - Center of Innovation, Lilly Deutschland GmbH
Senior Manager, Global HEOR & RWE, Oncology, Daiichi Sankyo Europe GmbH
Frankfurt, Germany
